Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06295367 · ClinicalTrials.gov registry record · NA

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

A NA study of Malignant Solid Neoplasm, sponsored by ECOG-ACRIN Cancer Research Group.

Recruiting
Registry status
NA
Development phase
760
Enrollment target
20
Study locations

NCT06295367 is a NA study of Malignant Solid Neoplasm that is actively recruiting participants, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 760 participants, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06295367, a NA study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by ECOG-ACRIN Cancer Research Group.

RECRUITING
Registry status
NA
Development phase
760 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.

Conditions Studied

Interventions

  • OTHER Survey Administration
  • OTHER Best Practice
  • OTHER Interview
  • OTHER Financial Navigation

Study Locations (20)

Colorado

  • Rocky Mountain Cancer Centers-Aurora - Aurora
  • Boulder Community Foothills Hospital - Boulder
  • Rocky Mountain Cancer Centers-Boulder - Boulder
  • Rocky Mountain Cancer Centers - Centennial - Centennial
  • The Women's Imaging Center - Denver
  • Colorado Blood Cancer Institute - Denver
  • Presbyterian - Saint Lukes Medical Center - Health One - Denver
  • Rocky Mountain Cancer Centers-Midtown - Denver
  • Rocky Mountain Cancer Centers-Rose - Denver
  • Mountain Blue Cancer Care Center - Swedish - Englewood
  • Rocky Mountain Cancer Centers - Swedish - Englewood
  • The Melanoma and Skin Cancer Institute - Englewood
  • Rocky Mountain Cancer Centers-Lakewood - Lakewood
  • Rocky Mountain Cancer Centers-Littleton - Littleton
  • Rocky Mountain Cancer Centers-Sky Ridge - Lone Tree

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • CARTI Cancer Center - Little Rock

California

  • Contra Costa Regional Medical Center - Martinez
  • BASS Medical Group - Lennon - Walnut Creek

Alaska

  • Fairbanks Memorial Hospital - Fairbanks

Trial Details

FieldValue
Enrollment Target 760 participants
Start Date 2024-02-29
Est. Completion 2027-12-01
Phase NA

Sponsor

ECOG-ACRIN Cancer Research Group

75 total trials

What the Registry Record Tells You About NCT06295367

The ClinicalTrials.gov registry entry for NCT06295367 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,137-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (33% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Survey Administration is the first listed.

NCT06295367 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT06295367 about?

NCT06295367 is a clinical study titled "Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)". This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, incom...

What is the current status of trial NCT06295367?

This trial is currently recruiting. It is a NA study. The enrollment target is 760 participants. The study started on 2024-02-29. Estimated completion is 2027-12-01.

What conditions does trial NCT06295367 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm.

What interventions are being tested in trial NCT06295367?

The interventions under investigation include: Survey Administration (OTHER), Best Practice (OTHER), Interview (OTHER), Financial Navigation (OTHER).

Who is sponsoring clinical trial NCT06295367?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06295367 being conducted?

This trial has 20 study locations across Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.